ELI LILLY AND COMPANY |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 835.4 USD | +0.44% |
|
+2.41% | +43.19% |
| 03:36pm | US FDA panel to vote on data, risk profile of Lilly Alzheimer's drug | RE |
| 01:00am | Novo Nordisk braces for generic challenge to Ozempic, Wegovy in China | RE |
Financials (USD)
| Sales 2024 * | 42.98B | Sales 2025 * | 52.62B | Capitalization | 749B |
|---|---|---|---|---|---|
| Net income 2024 * | 11.93B | Net income 2025 * | 16.55B | EV / Sales 2024 * | 17.8 x |
| Net Debt 2024 * | 18.07B | Net Debt 2025 * | 15B | EV / Sales 2025 * | 14.5 x |
| P/E ratio 2024 * |
62.2
x | P/E ratio 2025 * |
44.8
x | Employees | 43,000 |
| Yield 2024 * |
0.62% | Yield 2025 * |
0.72% | Free-Float | 99.8% |
More Fundamentals
* Assessed data
More news
Latest transcript on Eli Lilly and Company
More recommendations
More press releases
More news
| 1 day | +1.30% | ||
| 1 week | +3.68% | ||
| Current month | +3.02% | ||
| 1 month | +10.23% | ||
| 3 months | +8.38% | ||
| 6 months | +43.42% | ||
| Current year | +44.98% |
1 week
811.10
846.97
1 month
750.53846.97
Current year
579.05846.97
1 year
432.34846.97
3 years
201.83846.97
5 years
101.36846.97
10 years
58.50846.97
| Managers | Title | Age | Since |
|---|---|---|---|
David Ricks
CEO | Chief Executive Officer | 56 | 95-12-31 |
Ruth Gimeno
PSD | President | - | - |
David Hyman
CTO | Chief Tech/Sci/R&D Officer | - | 23-10-15 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 63 | 21-01-24 | |
Ralph Alvarez
BRD | Director/Board Member | 68 | 09-03-31 |
Jon Fyrwald
BRD | Director/Board Member | 63 | 04-12-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 6.49% | 17 M€ | +8.17% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-06-06 | 834.7 | +0.35% | 961 172 |
| 24-06-05 | 831.8 | -0.10% | 2,169,003 |
| 24-06-04 | 832.6 | +0.16% | 1,748,288 |
| 24-06-03 | 831.3 | +1.33% | 2,537,239 |
| 24-05-31 | 820.3 | +0.65% | 4,472,119 |
Delayed Quote Nyse, June 06, 2024 at 10:32 am EDT
More quotes
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
Pharmaceuticals
Calendar
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
831.8
USD
Average target price
852.5
USD
Spread / Average Target
+2.50%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +44.98% | 749B | |
| +39.45% | 605B | |
| -6.46% | 351B | |
| +19.84% | 328B | |
| +8.09% | 292B | |
| +11.81% | 216B | |
| -2.54% | 214B | |
| +1.74% | 167B | |
| +6.88% | 165B | |
| +1.19% | 123B |
- Stock Market
- Equities
- LLY Stock
